Today: 21 March 2026
Browse Category

NASDAQ:RCUS 13 January 2026

Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

Arcus Biosciences shares rose 4.8% to $22.32 Tuesday after Goldman Sachs upgraded the stock to “Buy” and raised its price target. The move followed early Phase 1 data for lead drug casdatifan showing response rates of 31% alone and 46% in combination for advanced kidney cancer. Arcus plans to present at the J.P. Morgan Healthcare Conference on Wednesday. The company reported $1 billion in cash and funding into late 2028.
13 January 2026

Stock Market Today

  • RTX Valuation in Focus After Earnings Beat and Revenue Growth
    March 21, 2026, 3:25 PM EDT. RTX (NYSE:RTX) reported 12.1% year-on-year revenue growth, surpassing analyst estimates by 7%, driven by strong sales, adjusted earnings per share (EPS), and free cash flow. The stock's share price closed at $198.16, with a mixed recent momentum: an 8.87% increase over 90 days but a 3.11% decline in the past week. Long-term shareholders have seen a 52.23% return over one year. Analysts estimate RTX is undervalued by 8.8%, with a fair value of $217.16, supported by a robust $236 billion backlog and growing international contracts amid rising global defense spending. However, discounted cash flow (DCF) models suggest the stock may be overvalued at current prices due to risks like tariff volatility and engine cost overruns. Investors face a choice between earnings power and cash flow perspectives on RTX's valuation.
Go toTop